全球 HIV 預防市場 (2021-2028)
Global Prophylactic HIV Drugs Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|全球 HIV 預防市場 (2021-2028) Global Prophylactic HIV Drugs Market - 2021-2028|
|出版日期: 2021年06月01日||內容資訊: 英文 180 Pages||
全球 HIV 預防藥物市場受到 HIV 感染者的增加、政府努力提高公眾意識以及持續的研發活動的推動。預計在預測期內，全球愛滋病毒感染者人數的增加將推動市場發展。
本報告調查了全球 HIV 預防藥物市場，按細分/地區對市場規模和增長率的市場、趨勢和預測、新型冠狀病毒感染 (COVID-19) 的影響分析以及市場增長進行了概述。它提供了對促進因素和限制因素、市場機會、競爭條件、主要公司概況等的分析。
The global prophylactic HIV drugs market size was worth US$ XX billion in 2019 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Human immunodeficiency virus (HIV) is a chronic, potentially life-threatening condition. By damaging the immune system, HIV targets the immune system and weakens people's defence against many infections and some types of cancer. HIV is a sexually transmitted infection, and it can also spread through contact with the infected blood or from mother to child during pregnancy, childbirth or breastfeeding. The most advanced stage of HIV infection is acquired immunodeficiency syndrome (AIDS), which can take many years to develop if not treated, depending on the individual. There's no cure for HIV/AIDS, but medications can dramatically slow the progression of the disease. Prophylactic drugs for HIV are used to prevent AIDS among people at high risk for the disease. Since AIDS is a viral, autoimmune disorder, the treatment is much more complicated than bacterial diseases. Thereby, the prevention of this disease is preferred over its cure, resulting in a growing demand for preventive HIV drugs worldwide.
The global prophylactic HIV drugs market growth is driven by the increasing prevalence of HIV infections, rising awareness by government initiatives among people about the HIV causes, symptom, precautions and treatment and Ongoing research and development activities.
Increasing prevalence of HIV infections globally, is expected to drive the global Prophylactic HIV Drugs market during the forecast period.
The prevalence of HIV infection is rapidly growing globally. The factors responsible for the increasing prevalence rate include the widespread use of contaminated needles or syringes, unprotected sex, and the lack of awareness about transmission mode. For example, according to data published by the World Health Organization, 38 million people lived with HIV in 2019. In that year, approximately 68% of adults and 53% of children living with HIV received lifelong antiretroviral therapy (ART). By June 2020, 26 million people were accessed antiretroviral therapy, marking a 2.4% increase from an estimate of 25.4 million at the end of 2019. The disease has affected mainly developing and underdeveloped countries on a larger scale due to the lack of adequate preventive measures and treatment facilities. The future growth of this market largely depends upon the treatment needs and unmet therapeutics in these countries.
Strong pipeline drugs, is expected to drive the global Prophylactic HIV Drugs market during the forecast period.
Many companies, such as Gilead Sciences, Inc. and Cipla, Inc., have also adopted patient education programs to reduce the adverse consequences of the infection. Moreover, several prophylactic HIV drugs for the treatment of HIV infection are currently in the pipeline. For instance, the Lenacapavir capsid inhibitor (GS-6207) of Gilead Sciences, Inc is currently under Phase II. It is being developed for the long-acting HIV treatment of virologically suppressed people living with HIV.
Major side effects of HIV drugs is likely to hinder the market growth
Side effects from HIV medicines include nausea, fatigue, and trouble sleeping are some short-term side effects. Other major side effects can lead to problems that may not appear for months or years after starting a medication. For instance, high cholesterol can be a side effect of some HIV medicines. High cholesterol is a risk factor for heart disease.
COVID-19 Impact Analysis
The covid-19 pandemic outbreak has enhanced the need to evaluate the antiretroviral drugs to treat COVID-19 infections. The drugs like lopinavir and ritonavir, which are used in combination to treat HIV, are reused to treat COVID-19 infections. Currently, many countries are evaluating the potential of these antiretroviral drugs for treating coronavirus infection. Manufacturers of these HIV drugs have also increased research activities and are also increasing the manufacturing capacities of these drugs as they are extensively used for symptomatic treatment of COVID-19.
Based on the Drug Type, the global prophylactic HIV drugs market is segmented into Tenofovir, Emtricitabine and Other drugs
Emtricitabine (commonly called FTC) drug accounts largest share of the global prophylactic HIV drugs market under the trade name Emtriva (formerly Coviracil), is a nucleoside reverse-transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection in adults and pediatrics. It is also marketed in a fixed-dose combination with tenofovir disoproxil (Viread) under the brand name Truvada and with tenofovir alafenamide (Vemlidy) under the brand name Descovy. A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved U.S FDA in July 12, 2006, under the brand name Atripla.
Tenofovir is an antiviral medicine used to treat HIV infection, which can cause acquired immunodeficiency syndrome (AIDS). Tenofovir is not a cure for HIV or AIDS. Tenofovir is also used to treat chronic hepatitis B. Viread (tenofovir disoproxil fumarate) is an oral nucleotide analog DNA polymerase inhibitor. DNA polymerase is the enzyme that is necessary for the virus to replicate in liver cells.
Based on the dosage type, the global prophylactic HIV drugs market is segmented into oral, topical
The oral dosage segment is expected to dominate the global prophylactic HIV drugs market during the forecast period. This can be attributed to novel product development and the presence of a robust pipeline coupled with rising product approvals. For instance, Merck developing HIV-1 infection MK-8591A (doravirine/islatravir) is currently under Phase 3, which the company says game-changer in the HIV drug market. The oral form also has several pharmacokinetic advantages, such as a higher rate of bioavailability, rapid drug delivery, and high efficacy, and the oral form is the most patient compliance route. Therefore, it is most widely adopted by patients. The market's future growth is anticipated to fuel by the launch of various potential pipeline candidates such as fostemsavir and PRO 140 and the launch of generic versions of various branded drugs such as tenofovir disoproxil fumarate tablets.
Based on distribution channel, the global prophylactic HIV drugs market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others
The retail pharmacies segment is expected to dominate during the forecast period. HIV oral medications are easily, readily available in retail pharmacies as the generic medicine. Retail pharmacies offer convenient services, including home delivery of medicines and availability of all types of drugs and medicines. Moreover, consumer preference for easy availability of products due to busy lifestyles and hectic work schedules is anticipated to boost HIV drugs market growth.
North America region holds the largest market share in the global prophylactic HIV drugs market
North America served the largest share of the market due to the increasing prevalence of HIV cases. As per the Department of Health & Human Services, an estimated 1.1 million people in the U.S. are living with HIV. According to the HIV Surveillance Report 2019 by the Government of Canada, in 2019 over 2,122 HIV diagnoses were reported in Canada 5.6 per 100,000 population. The age group 30 to 39-years had the highest HIV diagnosis rate at 12.7 per 100,000 population. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel treatments, the total availability of advanced technological tools, FDA approval of new drugs and many companies are developing anti-HIV drugs. In addition, there is an increasing incidence of the United States and Canadian government approval which is one of the major reasons propelling the growth. For instance, in September 2019 Merck received United States Food and Drug Administration (FDA) approval for two new HIV-1 medicines: Delstrigo and Pifeltro for commercialization of drugs in Canada and United States.
The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance,
The global prophylactic HIV drugs market is highly competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Merck Sharp & Dohme Corp, Mylan NV, Cipla Inc., Bristol-Myers Squibb Company, Genentech Inc., and Johnson & Johnson Health Care Systems Inc, Gilead Sciences Inc, ViiV Healthcare, AbbVie Inc, Theratechnologies Inc. The key players are adopting various growth strategies such as product launch, acquisitions and investments in multiple sectors. For instance, In August 2020, ViiV Healthcare received the United States Food and Drug Administration (FDA) approval for its Dovato, as a complete regimen for the treatment of HIV-1 infection.
Gilead Sciences, Inc
Overview: Gilead Sciences, Inc is an American biopharmaceutical company headquartered in Foster City, California, founded in 1987, with 14640 employees who focus on researching and developing antiviral drugs used to treat HIV, Hepatitis B, Hepatitis C, and Influenza, including Harvoni and Sovaldi. It is also a member of the NASDAQ Biotechnology Index and the S&P 500.
Product Portfolio: The Company's portfolio comprised of include HIV/AIDS, Oncology/ Hematology, Covid-19, Cardiovascular, Respiratory/Inflammation, Liver Diseases and Other medicines.
Product- In October 2019, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences' Descovy (emtricitabine and tenofovir alafenamide tablets) for a pre-exposure prophylaxis (PrEP) indication.
Two compounds named Unboosted protease inhibitor (GS-1156) and Long acting bictegravir (GS-9883) are under Phase I clinical trials for Long-acting HIV treatment.
The global prophylactic HIV drugs market report would provide an access to an approx. market data 61 tables, 53 figures and 240 pages.
LIST NOT EXHAUSTIVE